The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) study is a randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
Coordinating group: BrEAST
Learn more about ALTTO: http://alttotrials.com
Important information A planned interim review of early data from ALTTO has resulted in a change to the ongoing study. To learn more visit:
http://alttotrials.com http://ncctg.mayo.edu http://www.gsk.com
Start date: June 2007 Closure date: July 2011 Target nr. of patients: 8400 maximum Final accrual: 8381
Reason for closure: Reached target accrual